维康药业(300878) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for the third quarter was ¥36,747,869.47, a decrease of 50.25% compared to the same period last year[5] - The net profit attributable to shareholders was -¥59,634,910.76, representing a decline of 299.41% year-over-year[5] - The basic and diluted earnings per share were both -¥0.4119, down 300.64% from the previous year[5] - The company reported a significant decrease in sales revenue, down 59.20% year-over-year, primarily due to a reduction in the scope of consolidation[9] - Total operating revenue for the current period was ¥151,317,754.30, a decrease of 59.3% compared to ¥370,849,453.15 in the previous period[19] - The net profit for the current period was a loss of ¥123,825,528.73, compared to a profit of ¥46,205,071.06 in the previous period[20] - Basic and diluted earnings per share for the current period were both -0.8554, compared to 0.3046 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,488,003,292.41, a decrease of 9.94% from the end of the previous year[5] - Total current assets decreased from 616,482,282.11 to 533,014,005.98, a decline of approximately 13.5%[17] - Total assets decreased from 1,652,323,039.56 to 1,488,003,292.41, a decline of approximately 10.0%[17] - Total liabilities decreased significantly, with short-term borrowings reduced to zero from ¥10,008,861.11[9] - Total liabilities decreased from 240,381,545.98 to 228,006,590.93, a decrease of about 5.1%[17] - The total liabilities decreased to ¥458,370,823.65 from ¥478,498,028.63, reflecting a reduction of 4.2%[18] - The total equity attributable to shareholders decreased to ¥1,013,924,966.40 from ¥1,157,666,559.71, a decline of 12.4%[18] Cash Flow - The company's cash flow from operating activities showed a net increase of 222.01% year-to-date, totaling ¥42,981,468.28[5] - Cash inflow from operating activities totaled ¥211,358,666.73, a decrease of 42.4% from ¥366,200,480.17 in the previous period[22] - The net cash flow from operating activities was $42,981,468.28, a significant improvement compared to a net outflow of $35,228,627.08 in the previous period[23] - Total cash outflow from operating activities amounted to $168,377,198.45, while cash inflow from investment activities was $44,675,315.68, leading to a net cash flow from investment activities of $5,959,212.76[23] - Cash inflow from financing activities was $11,000,000.00, with total cash outflow from financing activities reaching $50,589,730.41, resulting in a net cash flow from financing activities of -$39,589,730.41[23] - The company experienced a net increase in cash and cash equivalents of $9,350,950.63 during the period[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,593[12] - Liu Zhongliang holds 60.89% of shares, amounting to 88,160,400 shares, with 31,000,000 shares pledged[12] Operational Efficiency - The cash flow from operating activities showed a positive trend, indicating improved operational efficiency[23] - The company has no new product launches or significant market expansion strategies mentioned in the report[15] Expenses - Total operating costs for the current period were ¥250,194,085.06, down 39.6% from ¥414,716,527.66 in the previous period[19] - Research and development expenses decreased to ¥7,664,570.90, down 37.5% from ¥12,180,680.93 in the previous period[20] - Financial expenses increased to ¥4,627,729.91 from ¥1,969,365.21, marking a rise of 134.5%[20] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may impact financial reporting[24] - The company did not undergo an audit for the third quarter financial report[24]